Last reviewed · How we verify
Majezik %0.25 oral spray
Majezik %0.25 oral spray is a Small molecule drug developed by Pamukkale University. It is currently in Phase 2 development. Also known as: Free gingival graft harvesting.
At a glance
| Generic name | Majezik %0.25 oral spray |
|---|---|
| Also known as | Free gingival graft harvesting |
| Sponsor | Pamukkale University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Majezik %0.25 oral spray CI brief — competitive landscape report
- Majezik %0.25 oral spray updates RSS · CI watch RSS
- Pamukkale University portfolio CI
Frequently asked questions about Majezik %0.25 oral spray
What is Majezik %0.25 oral spray?
Majezik %0.25 oral spray is a Small molecule drug developed by Pamukkale University.
Who makes Majezik %0.25 oral spray?
Majezik %0.25 oral spray is developed by Pamukkale University (see full Pamukkale University pipeline at /company/pamukkale-university).
Is Majezik %0.25 oral spray also known as anything else?
Majezik %0.25 oral spray is also known as Free gingival graft harvesting.
What development phase is Majezik %0.25 oral spray in?
Majezik %0.25 oral spray is in Phase 2.
Related
- Manufacturer: Pamukkale University — full pipeline
- Also known as: Free gingival graft harvesting
- Compare: Majezik %0.25 oral spray vs similar drugs
- Pricing: Majezik %0.25 oral spray cost, discount & access